

PROVISIONAL PROGRAMME AND CALL FOR ABSTRACTS

ILCA 2018

INTERNATIONAL LIVER CANCER ASSOCIATION

12th Annual Conference

14 ► 16 September 2018

London, United Kingdom

Hilton London Metropole



ILCA

International Liver Cancer Association

The international
multidisciplinary
forum for liver
cancer experts
around the latest
innovations in
research and care

KEY DATES

ABSTRACT SUBMISSION

6 April 2018

EARLY REGISTRATION

25 June 2018

REGULAR REGISTRATION

3 September 2018

LATE REGISTRATION

As of 4 September 2018

CONFERENCE FEATURES

- State-of-the-Art Lectures
- Cutting Edge Symposia
- General Sessions
- Interactive Workshops
- e-Poster Viewing Tour
- Industry Exhibition
- Pre-Conference Workshop

New this year!

- Young Investigator Session
- Grand Rounds Session
- Workshop for Nurses


Register now online www.ilca2018.org

The Conference

Priming Knowledge in Liver Cancer across Disciplines

ILCA is pleased to bring its annual conference to the vibrant city of London offering a programme with a multidisciplinary and transversal approach, with the objective to encourage and stimulate scientific debate and networking between liver cancer experts from all regions.

The Annual Conference is the leading scientific meeting in the liver cancer field connecting hundreds of international participants from all related disciplines to exchange the latest innovation, research and best practices in general sessions, symposia, workshops and networking sessions.



Who should Attend?

Clinical, translational and basic researchers, physicians and allied professionals across liver cancer related disciplines will convene at ILCA 2018 in London to share best practices and findings, making this event the premier forum for advancing research in the pathogenesis, prevention, and treatment of liver cancer.

Contributions from Participants

All participants are invited to make submissions for review by an Abstract Review Committee. The Committee will accept or reject the work according to the relevance to ILCA, objectivity of statements, suitability of methods, conclusions confirmed by objective results, scientific value, originality of work and overall impression. Selected submissions considered to have especially broad appeal will be assigned to General Sessions for presentation as Oral Communications. All other accepted submissions will be presented in e-Poster format. The e-Poster viewing tour will be opened by one of the ILCA prominent scientists and be partly dedicated to the top scored abstracts within each category, presented in paper board poster format.

How to Submit an Abstract

Abstracts may only be submitted electronically through the conference website www.ilca2018.org. Abstracts should address all aspects of liver cancer with a clear emphasis on maximizing focus, exchange and results. **The deadline for abstract submissions is 6 April 2018.** An opportunity to submit late breaking abstracts will be available.

Please visit www.ilca2018.org to review abstract categories and submission guidelines.

Highlighted Speakers



Richard Finn, MD (USA)

Richard Finn is an Associate Professor of Medicine in the Division of Hematology/Oncology at the UCLA David Geffen School of Medicine and co-director of the Signal Transduction Program in the Jonsson Comprehensive Cancer Center at UCLA. He currently splits his time between patient care and laboratory and clinical research. His research interests lie in the development of molecular targeted agents and biomarkers in liver cancer and breast cancer.



Tak Wah Mak, PhD (Canada)

Tak Wah Mak, PhD, is internationally known for his work in the molecular biology of cancer and the immune system, and a world leader in the genetics of immunology and cancer. In 1984, he led the group that discovered the T cell receptor, and his published work on the cloning of T cell antigen receptor genes has been cited over 1,200 times.



John Primrose, MD (United Kingdom)

Prof. John Primrose is Professor of Surgery at the University of Southampton, a post he has held since 1994. He trained in Glasgow and Leeds where he was Lecturer and then Senior Lecturer in Surgery. His clinical interest is in cancer, particularly hepatobiliary (HPB) cancer and Southampton is a large tertiary referral centre for HPB disease. It is the largest laparoscopic HPB centre in the United Kingdom.

Please visit www.ilca2018.org for a full overview of all distinguished international speakers

The Programme

- General Session
- Symposium
- State-of-the-Art Lecture
- Industry Symposium
- Workshop

Thursday, 13 September 2018

- 13:00 – 18:00** Pre-Conference Workshop on Perspective for Precision Medicine in HCC
 Chairs: *Sandrine Faivre, MD, PhD (France), Peter Schirmacher, MD, PhD (Germany) and Augusto Villanueva, MD, PhD (USA)*
The pre-conference workshop is subject to an additional registration. To attend this workshop, full conference registration is compulsory.
- 18:00 – 19:00** Young Investigator Session
 Chair: *Maria Reig, MD, PhD (Spain)*

Friday, 14 September 2018

- 08:00 – 09:30** ILCA Symposium 1: From Metabolic Syndrome to NASH and HCC
 - Role of Autophagy in Metabolic Syndrome and Liver Carcinogenesis
Anna Cuervo, MD, PhD (USA)
 - Involvement of Adaptive Immune Cells in NASH and NASH-HCC Transition
Mathias Heikenwälder, MD, PhD (Germany)
 - Modulating Metabolic Syndrome to Decrease Tumour Occurrence
Jean-François Dufour, MD, PhD (Switzerland)
- 09:30 – 10:15** State-of-the-Art Lecture 1: Targeting Genomic Instability in Liver Cancer: Dream or Reality?
Tak Wah Mak, PhD (Canada)
- 10:15 – 10:45** Coffee and Networking Break
- 10:45 – 11:00** Welcome Address
- 11:00 – 12:30** General Session 1
- 12:30 – 12:45** Session Break
- 12:45 – 14:15** Industry Partner Lunch Symposium
- 14:15 – 14:30** Session Break
- 14:30 – 16:00** General Session 2
- 16:00 – 16:30** Coffee and Networking Break
- 16:30 – 18:00** ILCA Symposium 2: Heterogeneity in HCC
 - Histological and Molecular Heterogeneity
Michael S. Torbenson, MD (USA)
 - HCC Heterogeneity Using Conventional and Functional Imaging
TBC
 - How to Target and Monitor HCC Heterogeneity in Clinical Trials?
Ann Lii Cheng, MD, PhD (Taiwan)
- 18:00 – 19:00** Welcome Reception

Saturday, 15 September 2018

- 07:30 – 08:30** Industry Partner Breakfast Symposium
- 08:30 – 10:00** General Session 3
- 10:00 – 11:00** Networking Break and e-Poster Viewing Tour
- 11:00 – 12:30** Presidential Session
- 12:30 – 12:45** Session Break
- 12:45 – 13:45** Industry Partner Lunch Symposium
- 13:45 – 14:00** Session Break
- 14:00 – 15:15** General Session 4
- 15:15 – 15:45** Coffee and Networking Break
- 15:45 – 17:15** ILCA Symposium 3: Debates
 - Liver Resection is Better than Radiofrequency
 - PRO: *Olivier Seror, MD, PhD (France)*
 - CON: *Kim Olthoff, MD (USA)*
 - Y90 Plays a Role in Advanced HCC
 - PRO: *Laura Kulik, MD (USA)*
 - CON: *Jordi Bruix, MD, PhD (Spain)*
 - Systemic Adjuvant Treatment for Intrahepatic Cholangiocarcinoma
 - PRO: *John Primrose, MD (United Kingdom)*
 - CON: *Katie Kelley, MD (USA)*
- 17:15 – 17:30** Session Break
- 17:30 – 18:30** Workshop 1: Molecular Diversity in HCC
 - Liquid Biopsy in HCC: Strengths and Limitations
Augusto Villanueva, MD (USA) and Irene Ng, MD, PhD (Hong Kong)
- Workshop 2: Systemic Therapy
 - How to Sequence Treatment
Andrew Zhu, MD, PhD (USA) and Bristi Basu, MD, PhD (United Kingdom)
- Workshop 3: Surgery for Primary Liver Cancer
 - Transplantation for Cholangiocarcinoma
Pierce Chow, PhD (Singapore) and Lewis Roberts, MD, PhD (USA)
- Workshop 4: Radiology
 - Integration of LI-RADS in Clinical Practice
Riccardo Lencioni, MD (Italy/USA)
- Workshop for Nurses

Sunday, 16 September

- 08:00 – 09:00** Industry Partner Breakfast Symposium
- 09:00 – 10:00** Joint HCC UK / ILCA Grand Rounds Session
- 10:00 – 10:45** State-of-the-Art Lecture 2: Systemic Therapy for HCC: Is there a Standard of Care?
Richard Finn, MD (USA)
- 10:45 – 11:00** Coffee and Networking Break
- 11:00 – 12:30** General Session 5
- 12:30 – 12:45** Closing Ceremony
- 12:45 – 13:00** Session Break
- 13:00 – 13:45** ILCA General Assembly

Registration

Registration must be completed online at www.ilca2018.org

Conference Registration Fees

	Early registration 25 June 2018	Regular registration 3 September 2018	Late registration As of 4 September 2018
ILCA Member*	€ 350	€ 450	€ 500
ILCA Non-Member	€ 575	€ 625	€ 675
Student, Scientist in Training and Nurse**	€ 150	€ 175	€ 200

Registration fees exclude 20% UK value added tax.

* Please note that ILCA delegates who have not paid their membership dues by 1 September 2018 will not be granted the reduced registration fee. ILCA member's registration fees will only be available after your application or renewal has been fully processed. To apply for or renew your membership, please visit www.ilca-online.org

** This fee is only available to those students who do not yet have their degree. A copy of your student ID card must be provided upon registration.

Cancellation and Refund Policy:

For cancellations received before or on 27 August 2018 a full refund will be provided minus a € 50 cancellation fee. As of 27 August 2018, no refund of registration fees will be possible.

All refunds are subject to prevailing exchange rates. Refunds will be made following the conference in the same manner as the original payment was received. If bank charges apply, they will be deducted from the refunded amount.

Venue

The venue for ILCA 2018 is the **Hilton London Metropole**, one of Europe's largest venues for international conferences with state-of-the-art facilities and located in the center of London.

Reserved rooms at the **Hilton London Metropole** with special rates for ILCA 2018 participants are available. Please visit the www.ilca2018.org website for further information.

Join and Participate in ILCA

Membership in ILCA provides you with exclusive benefits:

- Join a network of international liver cancer experts
- Participate in ILCA scientific events at a preferred rate
- Access the latest information on liver cancer related news and initiatives
- Get involved in association affairs
- Benefit from grants to support your research and enhance your career

Your membership is also essential to support ILCA's initiatives and to help progress its mission to advance research in the pathogenesis, prevention, and treatment of liver cancer. We invite you to discover more about ILCA's initiatives and to connect with our expanding group of liver cancer experts from various fields and from around the world.

To join ILCA and participate in its initiatives, please visit www.ilca-online.org

Pre-Conference Workshop on Perspective for Precision Medicine in HCC

Thursday, 13 September 2018

Registration fees	
ILCA Member*	€ 100
ILCA Non-Member	€ 125

To attend this workshop, full conference registration is compulsory.

Objectives:

- To understand molecular subclasses in liver cancer, and how they can assist in patient decision-making
- To recognise the opportunities and obstacles of developing predictive biomarkers to loco-regional or systemic therapies, including those derived from liquid biopsies
- To understand how to leverage on the interaction between immune and liver cancer cells for predictive and therapeutic purposes
- To learn about current and upcoming systemic therapies in liver cancer, including their main indications and limitations

Bedroom rates

King Room (single occupancy)	216 GBP*
King Room (double occupancy)	228 GBP*

*Room rate includes full buffet breakfast and VAT



ILCA Governing Board

Executive Committee

President
Morris Sherman (Canada)

Executive Secretary
Jessica Zucman-Rossi (France)

Treasurer
Bruno Sangro (Spain)

Past President
Richard Finn (USA)

Council

Sandrine Faivre (France)
Joong-Won Park (Republic of Korea)

Maria Reig (Spain)
Sasan Roayaie (USA)

Michiie Sakamoto (Japan)
Riad Salem (USA)

Eric Vibert (France)
Augusto Villanueva (USA)

Contact us

International Liver Cancer Association (ILCA)
Boulevard du Souverain, 280
B-1160 Brussels – Belgium
Tel: +32 2 789 2345
Fax: +32 2 743 1550
Email: info@ilca-online.org
Website: www.ilca-online.org

www.ilca2018.org • www.ilca-online.org

